Coronavirus COVID-19 Daily Update 11th April 2020

Coronavirus COVID-19 Daily Update 11th April 2020

This update will be published daily at 12pm GMT and aims to provide clinicians and the public with an overview of the latest data, guidelines, key publications and policy around COVID-19, with links to essential resources and information.


If you are a healthcare professional, please join the discussion on these latest COVID-19 cases on MedShr:

Please post any COVID-19 cases, images or learning points from your clinical practice on MedShr - share key knowledge and experience with a global network of doctors to help improve patient care. Include #COVID19 in your case title.


Please email COVID@medshr.net if you have any data, publications or information you would like to share.

Global Impact of COVID-19 to Date

As of 11th April 09:00 (GMT)

COVID-19 Cumulative Global Cases

As of 11th April 09:00 (GMT)

COVID-19 Global Active Cases Map

As of 11th April 09:00 GMT

Total UK COVID-19 Cases

As of 10th April

NB: Public Health England has now moved to a different reporting time for UK COVID-19 fatalities, as family consent is now needed to release mortality statistics. Hence the reported figures may not actually be the deaths that have taken place over the past 24 hours, meaning caution needs to be exercised when comparing figures from one day to the next.

COVID-19 Cumulative UK Cases

As of 10th April

COVID-19 Daily UK Cases

As of 10th April

COVID-19 Key Data

Source: BBC


Latest Developments


Africa

Asia

Middle East

Europe

United Kingdom

USA

Latest COVID-19 Publications

Some key recent publications to be aware of:

Transmission potential and severity of COVID-19 in South Korea

Published April 2020
International Journal of Infectious Diseases

Data from South Korea on the transmission of COVID-19 support the implementation of social distancing measures to rapidly control the outbreak

Covid-19: Why Germany’s case fatality rate seems so low

Published 7th April 2020
BMJ

Germany's low covid-19 fatality rate can be attributed partly to the nation’s early and high level of testing among a wide sample of the German population. While other countries were conducting a limited number of tests of older patients with severe cases of the virus, Germany was conducting many more tests that included milder cases in younger people.

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

Muthiah Vaduganathan, M.D., M.P.H., Orly Vardeny, Pharm.D., Thomas Michel, M.D., Ph.D., John J.V. McMurray, M.D., Marc A. Pfeffer, M.D., Ph.D., and Scott D. Solomon, M.D.

Published: March 30th 2020

Key points of this article: 

  • Initial COVID-19 reports (from China) led many to assume patients with hypertension to be overrepresented amongst the COVID-19 affected. However, the prevalence of hypertension is lower in COVID-19 patients than in the general population in China.

  • Only a small proportion of those with hypertension in China are thought to be taking RAAS inhibiting drugs (30-40% of hypertensives are medicated, and 20-30% of these take RAAS inhibitors)

  • Reports have not accounted for confounding factors and clearly age (a major risk factor for severity of COVID-19) increases the chance of having hypertension

  • Authors highlight a lack of evidence of effect of RAAS inhibitors in COVID-19 

  • They draw attention to an urgent need for guidance in this area, and express the opinion that clinicians be mindful of risks of abrupt withdrawal of RAAS inhibitors in high-risk patients


Comments

Sign in or Register to comment


Matching media queries: